|Reactivity||Human, Mouse, Rat|
|Calculated MW||14719 Da|
|Other Names||Fatty acid-binding protein, adipocyte, Adipocyte lipid-binding protein, ALBP, Adipocyte-type fatty acid-binding protein, A-FABP, AFABP, Fatty acid-binding protein 4, FABP4|
|Target/Specificity||A synthetic peptide corresponding to residues in human FABP4 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||FABP4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus (By similarity).|
|Cellular Location||Cytoplasm. Nucleus. Note=Depending on the nature of the ligand, a conformation change exposes a nuclear localization motif and the protein is transported into the nucleus. Subject to constitutive nuclear export (By similarity)|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Fatty acid binding proteins (FABPs) are proteins that reversibly bind fatty acids and other lipids. So far, nine tissue-specific cytoplasmic FABPs have been identified. Functions attributable to these lipid binding proteins remain unclear, but data are presented that indicate physiological roles in 1) fatty acid transport, esterification, and oxidation, 2) steroidogenesis, and 3) retinoid uptake, retinaldehyde reduction, and retinol esterification (1). Adipose tissue FABP (FABP4) binds both long chain fatty acids and retinoic acid (2). It delivers retinoic acid to nulear trans-acting proteins, thereby modulates genes coding for key proteins involved in lipid metabolism or differentiation. FABP4 is closely associated with metabolic syndrome, type 2 diabetes, and atheroscelerosis (3,4).
1. Clarke et al. FASEB J. 3 :2480-2487 ; 1989 2. Matarese et al. J. Biol. Chem. 263(28) :14544-51 ; 1988 3. Koh et al. Diabetes Care. 32 :147-52 ; 2009 4. Krusinova et al. Diabetes Res. Clin. Pract. 82 :S127-34 ; 2008
If you have any additional inquiries please email technical services at firstname.lastname@example.org.